Last updated: February 27, 2026
What Is the Drug Associated with NDC 65862-0922?
NDC 65862-0922 corresponds to VIAL 10.0 ML, NDC 65862-0922, which is identified as Vaxneuvance (Prevnar 13, Pneumococcal Conjugate Vaccine, 13-Valent). It is manufactured by Merck & Co. Inc. The vaccine is indicated for active immunization to prevent pneumococcal disease caused by Streptococcus pneumoniae serotypes included in the vaccine.
What Is the Current Market Landscape?
The pneumococcal vaccine market displays high competition, dominated by Merck's Vaxneuvance and Pfizer's Prevnar 20. Several factors influence market dynamics:
-
Market Size: The global pneumococcal vaccine market was valued at approximately $4.44 billion in 2021. It is projected to grow at a CAGR of 7.4% through 2028 [1].
-
Key Players: Merck (Vaxneuvance), Pfizer (Prevnar 20), and GlaxoSmithKline (Synflorix) are major players.
-
Patient Demographics: Target populations include infants, elderly, and immunocompromised patients. Vaccination rates vary by region, affecting demand.
-
Regulatory Status: Vaxneuvance received FDA approval in August 2021. It competes directly with Prevnar 13 (pre-2019) and Prevnar 20 (approved 2021). Insurance coverage policies influence accessibility.
What Are Price Trends and Projections?
Current Pricing Overview
-
List Price: In the U.S., the standard list price for a single dose of Vaxneuvance is approximately $150. Actual transaction prices are typically discounted 40-50% due to negotiations with payers and pharmacies [2].
-
Reimbursement Rates: Medicare Part D reimbursement can range between $80–$120 per dose, depending on contractual negotiations and regional factors.
-
Comparables: Prevnar 13 had list prices around $160 per dose prior to its replacement by Prevnar 20, which is priced at approximately $155–$165.
Price Drivers
-
Market Penetration: Increased adoption in adult and pediatric vaccination schedules influences demand and pricing stability.
-
Payer Negotiations: Payer leverage can lead to discounts. Contractual discounts typically reduce net prices by 30–50%.
-
Regulatory Approvals: Expanded indications (e.g., adult populations) can increase volumes, stabilizing or reducing unit prices over time.
-
Manufacturing Advances: Cost efficiencies in vaccine production can constrain price growth.
Future Price Projections (2023–2028)
- Expected Trends: Slight decline in net prices driven by increased volume, increased competition (e.g., Prevnar 20), and market saturation. List prices may remain stable or increase marginally with inflation.
| Year |
Estimated List Price |
Expected Net Price (after discounts) |
Volume Growth |
Market Impact |
| 2023 |
$150 |
$80–$120 |
+10% |
Stable or slight decline in net price |
| 2024 |
$150 |
$80–$115 |
+12% |
Increased demand in adult populations |
| 2025 |
$155 |
$85–$120 |
+8% |
Competitive pressure from Prevnar 20 |
| 2026 |
$155 |
$85–$115 |
+10% |
Market stabilization |
| 2027 |
$155 |
$85–$115 |
+7% |
Market saturation |
| 2028 |
$155 |
$85–$110 |
+5% |
Price stabilization |
Price Sensitivity & Regional Variations
-
Prices are most sensitive to negotiations with large payers like government health programs and private insurers.
-
Price differences exist internationally; U.S. prices tend to be higher than European markets due to regulatory and reimbursement differences.
Key Market Risks and Opportunities
Risks
-
Entry of Biosimilars: The vaccine is protein conjugate-based; biosimilar competition could compress prices.
-
Regulatory Delays: Additional approvals for expanded indications may slow market growth.
-
Pricing Pressures: Increasing attention on vaccine pricing from policymakers and payers.
Opportunities
-
Expanding Indications: Use in adolescents and adults could increase volume.
-
Market Penetration: Growing vaccination rates among the elderly and immunocompromised expand potential sales.
-
Global Growth: Emerging markets present growth opportunities, though prices there are significantly lower.
Summary
Vaxneuvance remains positioned as a leading pneumococcal conjugate vaccine in the U.S. market. Its price remains relatively stable with slight downward pressure expected over the next five years due to increased competition and market saturation. Its list prices hover around $150 per dose, with true transaction prices significantly negotiated downward. The market growth aligns with aging populations and expanded indications.
Key Takeaways
-
The US list price for NDC 65862-0922 is approximately $150 per dose, with net prices after discounts expected between $80 and $120.
-
Market growth through 2028 remains steady at around 5–8% annually, driven by increased vaccination among adults and the elderly.
-
Competitive pressures from Prevnar 20 and potential biosimilars could cause price compression.
-
International markets offer growth but at lower prices, affecting global revenue projections.
-
Market risks include regulatory delays and payer resistance; opportunities include expanded indications and emerging market penetration.
FAQs
-
What is the primary competitive advantage of Vaxneuvance?
Its inclusion of 13 serotypes offers broad coverage, with approval for use in both adults and children, providing versatility over competitors like Prevnar 13.
-
How does the pricing of Vaxneuvance compare to Prevnar 20?
The list price of Prevnar 20 is approximately $155–$165, slightly higher than Vaxneuvance, with negotiated actual prices often close due to market competition.
-
What factors influence the actual transaction price?
Negotiations with payers, volume discounts, regional policies, and rebate programs significantly impact the net price.
-
Is the market for pneumococcal vaccines expected to grow?
Yes, driven by aging populations, increased vaccination recommendations, and expanding indications.
-
How might biosimilar competition affect prices?
Entry of biosimilars could lead to price reductions and market share shifts, although biosⓘmilar development for vaccines faces regulatory challenges.
References
[1] MarketResearch.com. (2022). Global Pneumococcal Vaccine Market Analysis.
[2] Medicare Physician Fee Schedule Database. (2023). Reimbursement Rates for Pneumococcal Vaccines.
